Main Article Content
liraglutide, hypoglycemic response, predictive factors, type 2 diabetes mellitus
Background: Liraglutide is widely used in the treatment of type 2 diabetes mellitus (T2DM) because of its proven benefits in lowering blood glucose, reducing body weight, improving blood pressure, regulating blood lipids, and providing cardiovascular protection. However, liraglutide has been shown to be less effective in lowering glucose in some patients. The purpose of this study was to explore the factors affecting the glucose-lowering efficacy of liraglutide in patients with T2DM and to promote a rational basis for liraglutide application.
Methods: This was a retrospective cohort study involving patients with T2DM who were administered liraglutide once daily as a part of their diabetes care for at least 6 months. They were divided into two groups: responders (HbA1c decrease ≥1.0% or HbA1c <7.0% after 6 months of liraglutide treatment) and non-responders. The intergroup differences in the baseline data were analyzed, including basic profiles, test parameters, and comedications. The influencing factors of hypoglycemic efficacy were investigated using a binary logistic regression analysis.
Results: A total of 206 patients were included according to the inclusion criteria; 132 were responders and 74 were non-responders to liraglutide after 6 months of liraglutide therapy. According to the binary logistic regression analysis, age, baseline HbA1c, baseline postprandial plasma glucose (PPG), and duration of diabetes mellitus were found to be predictors of the hypoglycemic efficacy of liraglutide (P <0.05). A further linear regression analysis showed that patients with baseline HbA1c ≥7.31% had greater potential for response to liraglutide.
Conclusion: The identification of the abovementioned predictors for the hypoglycemic efficacy of liraglutide and the evaluation and prediction of the efficacy of liraglutide before its clinical application can facilitate individualized drug use.
2. Ji L, Lu J, Guo X, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectable. BMC Public Health. 2013;13:1-8.
3. Cornell SA. A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. J Clin Pharm Ther. 2013;38(3):181-189.
4. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.
5. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21.
6. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
7. Deng H, Lin S, Yang X, et al. Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients. J Diabetes. 2019;11(7):509-518.
8. American Diabetes A. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90-S102.
9. Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther. 2012;37(5): 510-524.
10. Pi-Sunyer X, Astrup A, Fujioka K, et al. Arandomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015, 373(1): 11-22.
11. Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide1 (GLP-1) receptor agonists. Cardiovasc Diabetol, 2014(13): 142.
12. Ji LN, Zhou DJ, Hong TP, et al. Expert guidance on clinical application of GLP-1 receptor agonist. Chin J Diabetes, 2018, 26(5) :35.
13. Haraguchi A, Fuji shima K, Ando T, et al. Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide. Minerva Endocrinol, 2014, 39 (4): 289-297.
14. Simioni N, Berra C, Boemi M, et al. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. Acta Diabetol, 2018, 55(6) :557-568.
15. Garber A, Henry R, Rather R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono) :a randomised, 52 -week , phaseⅢ, double-blind, parallel-treatment trial. Lancet, 2009, 373 (9662): 473-481.
16. Feng P, Yu D M, Chen LM, et al. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin, 2015, 36(2):200-208.
17. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial[J]. The Lancet, 2009, 373(9662):473-481.
18. Müssig K, Staiger H, Machicao F, Häring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia. 2010;53(11):2289-2297.
19. Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 2016;22(3):1260-1278.
20. Zhang YX, Zhang LY, Shen J, et al. A retrospective analysis of factors affecting the hypoglycemic efficacy of liraglutide in patients. Chinese Journal of Hospital Pharmacy, 2021, 41(18): 1895-1898.
21. Kong X, Xing X, Hong J, Zhang X, Yang W. Association of a type 2 diabetes genetic risk score with insulin secretion modulated by insulin sensitivity among Chinese Hans. Clin Genet. 2017;91(6):832-842.
22. NICE. NICE guidance on managing type 2 diabetes in adults. Prescriber. 2016;27(4):22-29.
23. Chinese Medical Association, Division of Diabetes. Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition) [J]. Chinese Journal of Diabetes,2021,13(04):315-409.
24. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., Bode, B., & LEAD-3 (Mono) Study Group (2009). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (London, England), 373(9662), 473–481.
25. Jones AG, McDonald TJ, Shields BM, et al. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2016;39(2):250-257.
26. Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017;54(12):1101-1114.
27. Khan M, Ouyang J, Perkins K, Nair S, Joseph F. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus. J Diabetes Res. 2015;2015:162718.
28. Jones AG, McDonald TJ, Shields BM, et al. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2016;39(2):250-257.
29. Kuwata H, Yabe D, Murotani K, Fujiwara Y, Haraguchi T, Kubota S, Kubota-Okamoto S, Usui R, Ishitobi M, Yamazaki Y, Hamamoto Y, Kurose T, Seino Y, Yamada Y, Seino Y. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 d
30. Penfornis A, Gourdy P, Martinez L, et al. Diabetes duration and background diabetes therapies in predicting liraglutide treatment response: data from the post-marketing EVIDENCE study[C]//Diabetologia. 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER, 2013, 56: S356-S356.
31. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications 2013;27: 87–91
32. Thong KY, McDonald TJ, Hattersley AT, et al. The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabet Med 2014;31: 403–411